OBJECTIVES: France has a high prevalence of chronic hepatitis C (HCV) and clinical impacts of the disease are well recognized.  Despite this, information on utility and health-related quality of life (HRQoL) is limited.  While it is generally accepted that HCV patients have reduced HRQoL, delineation of these values by disease stage and treatment outcome is not clear.  These differences are important for determining the benefits of treating patients and preventing disease progression.  This study assessed utility values of HCV patients in France by disease stage and treatment outcome.  METHODS: Physicians treating HCV patients in France were recruited to participate in the Hepatitis C Disease Specific Programme®.  From October 2012 thru January 2013, physicians completed Patient Record Forms for 10 consecutive patients presenting to their clinic.  Information included patient demographics, disease stage, and treatment outcome.   Patients completed the EQ-5D Index and EQ-VAS; these are standardized, preference-based measures of health.  Results were reported in descriptive and stratified analyses.  Linear regression analyses were performed to determine the independent associations with the EQ-5D. RESULTS: There were 297 matched physician and patient response forms.  Mean patient age was 50 years and 64% were male.  Mean EQ-5D Index was 0.764 (SD=0.283; range=-0.199-1.000).  Mean EQ-VAS was 65.85 (SD=21.00; range=5-100).  EQ-5D Index and EQ-VAS scores were significantly lower with worsening disease severity.  Among patients who had completed treatment, EQ-5D scores were higher for patients who achieved sustained virologic response (SVR) compared to those who did not (EQ-5D Index=0.873 vs. 0.660, p-value=0.0035).  Regression models showed higher age and worsening disease severity were significantly associated with lower EQ-5D Index and EQ-VAS scores. CONCLUSIONS: In a cross-sectional sample of HCV patients in France, utilities are linearly and significantly associated with disease progression, SVR, and age.  This information will be used to understand the benefits of treating patients and preventing disease progression.